435 related articles for article (PubMed ID: 34268530)
1. An update on acalabrutinib to treat chronic lymphocytic leukemia.
Blackmon A; O'Brien S
Drugs Today (Barc); 2021 Jul; 57(7):417-431. PubMed ID: 34268530
[TBL] [Abstract][Full Text] [Related]
2. Acalabrutinib: a bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia.
Wolska-Washer A; Robak T
Expert Rev Hematol; 2022 Mar; 15(3):183-194. PubMed ID: 35296194
[TBL] [Abstract][Full Text] [Related]
3. Acalabrutinib and its use in treatment of chronic lymphocytic leukemia.
Khan Y; O'Brien S
Future Oncol; 2019 Feb; 15(6):579-589. PubMed ID: 30381956
[TBL] [Abstract][Full Text] [Related]
4. Acalabrutinib: a highly selective, potent Bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia.
Ghia P; Dlugosz-Danecka M; Scarfò L; Jurczak W
Leuk Lymphoma; 2021 May; 62(5):1066-1076. PubMed ID: 33427570
[TBL] [Abstract][Full Text] [Related]
5. Assessing the pharmacokinetics of acalabrutinib in the treatment of chronic lymphocytic leukemia.
Miao Y; Xu W; Li J
Expert Opin Drug Metab Toxicol; 2021 Sep; 17(9):1023-1030. PubMed ID: 34275396
[TBL] [Abstract][Full Text] [Related]
6. Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia.
Woyach JA; Blachly JS; Rogers KA; Bhat SA; Jianfar M; Lozanski G; Weiss DM; Andersen BL; Gulrajani M; Frigault MM; Hamdy A; Izumi R; Munugalavadla V; Quah C; Wang MH; Byrd JC
Cancer Discov; 2020 Mar; 10(3):394-405. PubMed ID: 31915195
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells.
Patel V; Balakrishnan K; Bibikova E; Ayres M; Keating MJ; Wierda WG; Gandhi V
Clin Cancer Res; 2017 Jul; 23(14):3734-3743. PubMed ID: 28034907
[No Abstract] [Full Text] [Related]
8. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.
Sharman JP; Egyed M; Jurczak W; Skarbnik A; Pagel JM; Flinn IW; Kamdar M; Munir T; Walewska R; Corbett G; Fogliatto LM; Herishanu Y; Banerji V; Coutre S; Follows G; Walker P; Karlsson K; Ghia P; Janssens A; Cymbalista F; Woyach JA; Salles G; Wierda WG; Izumi R; Munugalavadla V; Patel P; Wang MH; Wong S; Byrd JC
Lancet; 2020 Apr; 395(10232):1278-1291. PubMed ID: 32305093
[TBL] [Abstract][Full Text] [Related]
9. Matching-adjusted indirect comparisons of safety and efficacy of acalabrutinib versus other targeted therapies in patients with treatment-naïve chronic lymphocytic leukemia.
Davids MS; Telford C; Abhyankar S; Waweru C; Ringshausen I
Leuk Lymphoma; 2021 Oct; 62(10):2342-2351. PubMed ID: 33955326
[TBL] [Abstract][Full Text] [Related]
10. The role of acalabrutinib in adults with chronic lymphocytic leukemia.
Fakhri B; Andreadis C
Ther Adv Hematol; 2021; 12():2040620721990553. PubMed ID: 33613932
[TBL] [Abstract][Full Text] [Related]
11. Acalabrutinib and its use in the treatment of chronic lymphocytic leukemia.
Egyed M; Lueff S; Borbely J; Illes A
Future Oncol; 2022 Mar; 18(7):755-769. PubMed ID: 35139644
[TBL] [Abstract][Full Text] [Related]
12. Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib.
Awan FT; Schuh A; Brown JR; Furman RR; Pagel JM; Hillmen P; Stephens DM; Woyach J; Bibikova E; Charuworn P; Frigault MM; Hamdy A; Izumi R; Linghu B; Patel P; Wang MH; Byrd JC
Blood Adv; 2019 May; 3(9):1553-1562. PubMed ID: 31088809
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia.
Rogers KA; Thompson PA; Allan JN; Coleman M; Sharman JP; Cheson BD; Jones D; Izumi R; Frigault MM; Quah C; Raman RK; Patel P; Wang MH; Kipps TJ
Haematologica; 2021 Sep; 106(9):2364-2373. PubMed ID: 33730844
[TBL] [Abstract][Full Text] [Related]
14. Acalabrutinib and Its Therapeutic Potential in the Treatment of Chronic Lymphocytic Leukemia: A Short Review on Emerging Data.
Isaac K; Mato AR
Cancer Manag Res; 2020; 12():2079-2085. PubMed ID: 32256115
[TBL] [Abstract][Full Text] [Related]
15. EMA Review of Acalabrutinib for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia.
Delgado J; Josephson F; Camarero J; Garcia-Ochoa B; Lopez-Anglada L; Prieto-Fernandez C; van Hennik PB; Papadouli I; Gisselbrecht C; Enzmann H; Pignatti F
Oncologist; 2021 Mar; 26(3):242-249. PubMed ID: 33486852
[TBL] [Abstract][Full Text] [Related]
16. US Food and Drug Administration approvals for Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukemia: Potential inefficiencies in trial design and evidence generation.
Kim MS; Prasad V
Cancer; 2020 Oct; 126(19):4270-4272. PubMed ID: 32644193
[TBL] [Abstract][Full Text] [Related]
17. Treatment of Chronic Lymphocytic Leukemia After Discontinuation of Bruton's Tyrosine Kinase Inhibitors.
Thompson MC; Mato AR
Hematol Oncol Clin North Am; 2021 Aug; 35(4):793-806. PubMed ID: 34174986
[TBL] [Abstract][Full Text] [Related]
18. Incorporating acalabrutinib, a selective next-generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies.
Danilov AV; Persky DO
Br J Haematol; 2021 Apr; 193(1):15-25. PubMed ID: 33216986
[TBL] [Abstract][Full Text] [Related]
19. ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
Ghia P; Pluta A; Wach M; Lysak D; Kozak T; Simkovic M; Kaplan P; Kraychok I; Illes A; de la Serna J; Dolan S; Campbell P; Musuraca G; Jacob A; Avery E; Lee JH; Liang W; Patel P; Quah C; Jurczak W
J Clin Oncol; 2020 Sep; 38(25):2849-2861. PubMed ID: 32459600
[TBL] [Abstract][Full Text] [Related]
20. Acalabrutinib, A Second-Generation Bruton's Tyrosine Kinase Inhibitor.
Kriegsmann K; Kriegsmann M; Witzens-Harig M
Recent Results Cancer Res; 2018; 212():285-294. PubMed ID: 30069636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
